Everything below concerns WADA prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In Italian, they are called pinoli (in the US, they are often called pignoli, but in Italy, pignolo is actually a word far more commonly used to describe a fussy, overly fastidious or extremely meticulous person) and are an essential component of Italian pesto sauce; the upsurge in the popularity of this sauce since the 1990s has increased the visibility of the nut in America, primarily on the West Coast. Torta della nonna (literally "granny's cake") is a generic Italian dish name that in most families indicates an old family recipe for any cake but often is used for a tart or a pie filled with custard, topped with pine nuts and optionally dusted with icing sugar. Pignoli cookies, an Italian American specialty confection (in Italy, these would be called biscotti ai pinoli), are made of almond flour formed into a dough similar to that of a macaroon and then topped with pine nuts. In the Catalan-speaking regions of Spain, a sweet called panellets is made of small marzipan balls covered with pine nuts, painted with egg, and lightly cooked. Pine nuts are also featured in the salade landaise of southwestern France. Nevada, or Great Basin, pine nut has a sweet fruity flavor and is promoted for its large size, sweet flavor, and ease of peeling.
=== Hormones === Many hormones can induce insulin resistance including cortisol, growth hormone, and human placental lactogen. Cortisol counteracts insulin and can lead to increased hepatic gluconeogenesis, reduced peripheral utilization of glucose, and increased insulin resistance. It does this by decreasing the translocation of glucose transporters (especially GLUT4) to the cell membrane. Based on the significant improvement in insulin sensitivity in humans after bariatric surgery and rats with surgical removal of the duodenum, it has been proposed that some substance is produced in the mucosa of that initial portion of the small intestine that signals body cells to become insulin resistant. If the producing tissue is removed, the signal ceases and body cells revert to normal insulin sensitivity. No such substance has been found as yet, and the existence of such a substance remains speculative. Leptin is a hormone produced from the ob gene and adipocytes. Its physiological role is to regulate hunger by alerting the body when it is full. Studies show that lack of leptin causes severe obesity and is strongly linked with insulin resistance.
=== Roman era === During the Roman era there was a settlement named Abona at the present Sea Mills; this was important enough to feature in the 3rd-century Antonine Itinerary which documents towns and distances in the Roman empire, and was connected to Bath by a road. Archaeological excavations at Abona have found a street pattern, shops, cemeteries and wharves, indicating that the town served as a port. Another settlement at what is now Inns Court, Filwood, had possibly developed from earlier Iron Age farmsteads. There were also isolated villas and small settlements throughout the area, notably Kings Weston Roman Villa and another at Brislington.
Dietary changes have been shown to significantly help people manage diabetes. There are many diets that are effective at managing diabetes however, it is important that patients understand that there is no one diet that all patients should use. Some diets that have strong evidence and have commonly been used successfully in diabetes management and assist with weight loss include Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH), Alternative Healthy Eating Index (AHEI), vegetarian, low carb, or carb-controlled. In addition, it is recommended that individuals choose a diet that can be adhered to long-term. Even in the most ideal diet becomes impractical if the patient has difficulty following it. While not advocating for a particular diet, the American Diabetes Association does recommend using the "Diabetes Plate Method" as a way to balance food groups. In this method, a 9 inch plate is divided into thirds, with 50% containing non-starchy vegetables, 25% protein, and 25% carbohydrates. Patients should avoid excess simple carbs or added fat (such as butter, salad dressing) and instead eat complex carbohydrates such as whole grains. In addition, patients should also avoid consumption of processed meat and foods and sugar-sweetened beverages. In the long term, it is helpful to eat a consistent diet and amount of carbohydrate to make blood sugar management easier. It is important for patients to eat 3 meals a day in order to reduce the chances of hypoglycemia, especially with patients that take insulin.
=== Oxidation-reduction === A reducing sugar is one that reduces another compound and is itself oxidized; that is, the carbonyl carbon of the sugar is oxidized to a carboxyl group. A sugar is classified as a reducing sugar only if it has an open-chain form with an aldehyde group or a free hemiacetal group.
Sources: en.wikipedia.org
== Operations == Salad and Go vertically integrated operations and distribution, sourcing ingredients directly from local farmers and suppliers whenever possible. The chain operates two food production facilities–one in Arizona and one in Texas–which prepare produce directly from farms and deliver it to stores. The average Salad and Go store size is approximately 1,000 square feet. This smaller model allows the stores to be built quickly in targeted areas while minimizing costs. Restaurants lack certain features of typical fast-food establishments like freezers, boilers, or fryers that require inspection before opening. Every Salad and Go store had a drive-through lane and a pickup window for orders placed in the drive-through, online or through the Salad and Go mobile app. The brand offered no on-site dining.
Luteinizing hormone subunit beta also known as lutropin subunit beta or LHβ is a polypeptide that in association with an alpha subunit common to all gonadotropin hormones forms the reproductive signaling molecule luteinizing hormone. In humans it is encoded by the LHB gene.
4-Aminobenzoic acid (also known as para-aminobenzoic acid or PABA because the two functional groups are attached to the benzene ring across from one another in the para position) is an organic compound with the formula H2NC6H4CO2H. PABA is a white crystalline solid, although commercial samples can appear gray. It is slightly soluble in water. It consists of a benzene ring substituted with amino and carboxyl groups. The compound occurs extensively in the natural world.
=== Pyrimidines === Uridine phosphorylase or pyrimidine-nucleoside phosphorylase substitutes the anomeric-carbon-bonded phosphate of ribose 1-phosphate for the free base uracil, forming the nucleoside uridine. Uridine kinase (aka uridine–cytidine kinase) can then phosphorylate the 5’-carbon of this nucleoside into uridine monophosphate (UMP). UMP/CMP kinase (EC 2.7.4.14) can phosphorylate UMP into uridine diphosphate, which nucleoside diphosphate kinase can phosphorylate into uridine triphosphate. Thymidine phosphorylase or pyrimidine-nucleoside phosphorylase adds 2-deoxy-alpha-D-ribose 1-phosphate to thymine, with thymine bonding at the anomeric carbon of the deoxyribose, forming the deoxynucleoside thymidine. Thymidine kinase can then phosphorylate the 5’-carbon of this compound into thymidine monophosphate (TMP). Thymidylate kinase can phosphorylate TMP into thymidine diphosphate, which nucleoside diphosphate kinase can phosphorylate into thymidine triphosphate. The nucleosides cytidine and deoxycytidine can be salvaged along the uracil pathway by cytidine deaminase, which converts them to uridine and deoxyuridine, respectively. Alternatively, uridine–cytidine kinase can phosphorylate them into cytidine monophosphate (CMP) or deoxycytidine monophosphate (dCMP). UMP/CMP kinase can phosphorylate (d)CMP into cytidine diphosphate or deoxycytidine diphosphate, which nucleoside diphosphate kinase can phosphorylate into cytidine triphosphate or deoxycytidine triphosphate.
Sources: en.wikipedia.org
=== Laboratory synthesis === The chemical synthesis of psilocybin has been described. Albert Hofmann and colleagues first synthesized psilocybin in 1958. Since then, various chemists have improved the methods for laboratory synthesis and purification of psilocybin. In particular, Shirota and colleagues reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4-hydroxyindole that does not require chromatographic purification. Fricke and colleagues described an enzymatic pathway for the synthesis of psilocybin and psilocin, publishing their results in 2017. Sherwood and colleagues significantly improved upon Shirota's method (producing at the kilogram scale while employing less expensive reagents), publishing their results in 2020.
Of the main cast from season 2, only seven returned in leading roles; Zendaya, Schafer, Sweeney, Apatow, Jacob Elordi, Alexa Demie, and Eric Dane. On February 19, 2026, Dane died of ALS after having completed his work on the season. Nika King, who portrayed Leslie Bennett, was demoted to a guest star. Barbie Ferreira, who portrayed Kat Hernandez, announced via Instagram on August 24, 2022 her decision to leave the series. She elaborated in a statement on April 5, 2023: "I just felt like, maybe it's like I overstayed my welcome a little bit. So for me, I actually felt good to be like, 'Okay, I get to not worry about this, and we both don't get too worried about this', because it's exhausting." Storm Reid, who portrayed Gia Bennett, was confirmed to not return in November 2024, with Algee Smith and Austin Abrams, who portrayed Chris McKay and Ethan Daley respectively, departing in February 2025. Javon Walton's character Ashtray died in season 2. Dominic Fike's character Elliot was reported to appear in the season, but did not. Season 2 guest stars Martha Kelly and Chloe Cherry, who portrayed Laurie and Faye Valentine respectively, were promoted to the main cast. Adewale Akinnuoye-Agbaje and Toby Wallace also joined the main cast as Alamo Brown and Wayne. Rosalía, Marshawn "Beast Mode" Lynch, Kadeem Hardison, Darrell Britt-Gibson, Priscilla Delgado, James Landry Hébert, Anna Van Patten, Sharon Stone and Asante Blackk were also announced to have joined the cast in recurring roles.
Thereby, the authors of the study were able to deliver fluorescent antigen binding proteins into cells facilitating live-cell immunostaining. However, few in vivo studies have succeeded. In one study, in vivo delivery of TAT- or penetratin-crosslinked Fab fragments yielded varied organ distributions and an overall increase in organ retention, which showed tissue localization. A non-covalent method that forms CPP/protein complexes has also been developed to address the limitations in covalent methods, such as chemical modification before crosslinking, and denaturation of proteins before delivery. In one study, a short amphipathic peptide carrier, Pep-1, and protein complexes have proven effective for delivery. It was shown that Pep-1 could facilitate rapid cellular uptake of various peptides, proteins, and even full-length antibodies with high efficiency and less toxicity. This approach has greatly simplified the formulation of reagents.
In a meta-analysis of various trials involving fluoxetine (Prozac), fluvoxamine (Faverin/Luvox), and sertraline (Zoloft) to test their relative efficacies in treating OCD, clomipramine was found to be significantly more effective. Other studies have borne similar results even when risk of bias is eliminated. A potentially significantly greater inherent side-effect profile, however, makes it a second-line choice in the treatment of OCD. SSRIs are generally better-tolerated but appear to be inferior in terms of actual clinical efficacy.
==== Novel agents ==== Several newer agents, including temozolomide and bendamustine, have activity in relapsed SCLC. Of note, temozolomide yielded a response rate of 38% for brain metastases due to SCLC. In a clinical trial of 50 patients, a combination of olaparib and temozolomide in relapsed small-cell lung cancer yielded an overall response rate of 41.7%, median progression-free survival of 4.2 months, and overall survival was 8.5 months. Lurbinectedin showed an increased overall survival rate in relapsed small cell lung cancer in a trial. Lurbinectedin is As of 2019 available in the U.S. under an expanded access program (EAP). Trilaciclib, a CKD4/6 inhibitor, reduces chemotherapy-induced toxicity in patients being treated for small-cell lung cancer. In 2021, the FDA approved trilaciclib (Cosela) as a treatment to reduce the frequency of chemotherapy-induced myelosuppression for patients receiving certain types of chemotherapy for extensive-stage small-cell lung cancer.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.